Clinical history listed as "pain," no comparison studies provided, patient motion and suboptimal positioning limit diagnostic detail. Sound familiar?
STUDY TYPE: Noncontrast CT chest/abdomen/pelvis. Please note absence of enhancement impairs parenchymal assessment.
CLINICAL HISTORY: "Pain." (Please note lack of pertinent historical details may limit diagnostic accuracy.)
COMPARISONS: None provided. If reports, or preferably images, from previous studies can be supplied, interpretation will improve, and an addendum may be generated.
TECHNIQUE: Axial imaging of the chest, abdomen, and pelvis was performed. Coronal and sagittal reconstructions are not provided, and some pathology may therefore not be appreciated. Patient's motion and failure to suspend respiration limit diagnostic detail. There is also substantial beam-hardening from habitus and suboptimal positioning, with upper extremities not removed from the field of view. Upper margin of study does not entirely cover the thoracic apex. Lower margin of study partially excludes the pelvis and perineum. Artifact from patient's jewelry and metallic items in clothing (none of which have been removed for study) also limits visibility.
FINDINGS: Heart and major thoracic vasculature are grossly unremarkable on this non-gated study. Against the background of motion artifact, lungs are predominantly clear although tiny nodular densities and subtle pneumonitis are not reliably excluded. No bulky lymphadenopathy is seen but early metastatic disease could still be present.
Tiny hypoattenuating foci are questioned in liver, spleen, pancreas, and kidneys, nonspecific. Liver and spleen are prominent but this could relate to patient habitus. Borderline-thickening of the adrenals is indeterminate. Gallbladder is present, without definite pathology although this modality is limited for such determination. Ureters are not reliably followed and phleboliths are indistinguishable from small stones of the distal tract, bilaterally.
Bladder is nondistended and not reliably assessed. No appreciable uterine/adnexal pathology by this modality; consider ultrasound if clinically appropriate. Appendix not reliably seen, and much of bowel is decompressed; enteritis cannot be excluded. Small quantity of free pelvic fluid is seen, possibly physiological but potentially pathological. No definite free air, although small quantities are difficult to distinguish from gas in closely-adjacent bowel segments. Degenerative changes within the axial skeleton may be related to patient age and habitus but more significant arthropathy is possible. Radionuclide bone scan may be more reliable for metastatic assessment.
IMPRESSION: No definite pathology, allowing for some limitations mentioned above.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.